Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTRANSDERMALStandard

NEUPRO

ROTIGOTINE

Standard Dose
6MG/24HR
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview NEUPRO is listed in Drugs@FDA under application 021829 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ROTIGOTINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 6MG/24HR Sponsor UCB INC Submission history Latest submission status date: 2021-07-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEUPRO is listed in Drugs@FDA under application 021829 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ROTIGOTINE Form and strength FILM, EXTENDED RELEASE;TRANSDERMAL - 6MG/24HR Sponsor UCB INC Submission history Latest submission status date: 2021-07-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.